Kemwell signs agreement with Mercury Pharma Group Ltd2012-11-30 12:27
Kemwell AB today signs an agreement with Mercury Pharma Group Ltd for contract manufacture of pharmaceuticals in the new state-of-the-art production facility in Uppsala. “This agreement shows that we are indeed competitive in Sweden in production. Our new modern facility gives great opportunities for pharmaceutical manufacture in collaboration with both new and existing customers,” says the company’s CEO Agneta Bergvall.
Kemwell is a Swedish-Indian contract manufacturer with production facilities in both India and Sweden. Kemwell established themselves on the European market six years ago when they acquired a facility from Pfizer. Here the company manufactures tablets, suppositories and capsules. Strong business development has allowed Kemwell to double their production space in Sweden through expansion in new facilities.
Mercury Pharma Group Ltd is an international pharmaceutical company specializing in the sale of prescription drugs. The company’s products are marketed worldwide with a focus on the European market. Kemwell’s agreement with Mercury Pharma Group Ltd covers manufacture of tablets and release and distribution of products to Great Britain and Ireland.
“It is always exciting to start a new collaboration with a client,” says Agneta.
“We aim to serve our customers with the highest levels in quality and service, ensuring that the customer gets the right product at the right time. At Kemwell we strive daily to live up to our ambition of being a contract manufacturer of merit and to help our clients become more competitive. We focus on being a continually developing company with a reputation for trustworthiness and dedication” says Agneta.
For more information, please contact:
Agneta Bergvall, CEO, Kemwell AB, +46-18-164504, firstname.lastname@example.org
Leo Fallgren, Manager Business Development, Kemwell AB, +46-18-164117,
Kemwell AB is a part of the family-owned Kemwell Biopharma Pvt Ltd in India with its headquarters in Bangalore, India. Kemwell is a leading CDMO for pharmaceuticals and biopharmaceuticals for global distribution. The company develops and manufactures pharmaceuticals for five of the world’s top ten pharmaceutical companies, including GlaxoSmithKline, Johnson & Johnson, Novartis and Pfizer. Kemwell is one of India’s largest pure-play contract manufacturers of pharmaceuticals with over 30 years’ experience. The company group has more than 1200 employees and seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets.
Read more about Kemwell on www.kemwellbiopharma.com